Jason Chan Email

VP, Quality Assurance . Adicet Bio

Menlo Park, CA

Location

j****@adicetbio.com

Primary Email

Current Roles

Employees:
170
Revenue:
$42.7M
About
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs). Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating TCR-like MAbs (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs can be used to arm T cells, as T cell engagers or as Antibody Drug Conjugates (ADC). In August 2016, Adicet entered a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology. Adicet Bio raised $51M in series A financing led by OrbiMed Partners, OrbiMed Israel, Novartis Venture Fund and Pontifax.
Adicet Bio Address
1000 Bridge Parkway
Menlo Park, CA
United States
Adicet Bio Email

Past Companies

Adicet Bio, IncVice President, Quality Assurance
Encoded Therapeutics Inc.Sr. Director, Quality
Encoded Therapeutics Inc.Director of Quality

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.